CAR T Cell Therapy News

Breast Cancer Cell 500X500

City of Hope is accelerating the development of treatment options for patients with breast cancer who have challenging tumors and poor prognosis with a phase 1 clinical trial that is enrolling patients with refractory HER2-positive breast cancer with brain metastases to test the safety and effectiveness of CAR T cell therapy.


brain tumor

City of Hope has opened a first-in-human clinical trial for patients with recurrent glioblastoma – the trial is the first to combine City of Hope’s unique CAR T cell therapy with immune checkpoint inhibitors.


News Image

The trial, which received a $4.1 million in grants from the National Institutes of Health and Gateway for Cancer Research, combines City of Hope’s unique CAR T cell therapy with immune checkpoint inhibitors

Larry Kwak

City of Hope’s research on the new CAR T therapy, published in Science Translational Medicine, offers hope for patients who have relapsed after commercially available CD19 immunotherapy treatments.


News Image

City of Hope’s research on the new CAR T, published in Science Translational Medicine, offers hope for patients who have relapsed after commercially available CD19 immunotherapy treatments.

News Image

The trial is one of the first CAR T cell trials nationwide to enroll prostate cancer patients.

HPV cells

HPV16-induced cancers, a strain that causes about 70% of all cervical cancers worldwide, are ideal candidates for targeted T cell therapy due to their nonself antigens.


Breakthroughs - prostate cancer clinical trial

In this phase 1 trial, the safety and tolerability of autologous anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T lymphocytes are studied in adult patients with PSCA+ metastatic castration-resistant prostate cancer.


Saul Priceman | City of Hope

Saul Priceman, Ph.D., and his research team have received a $9.28 million award from the California Institute for Regenerative Medicine to support a CAR T cell phase 1 clinical trial for the treatment of women with HER2-positive breast cancer that has spread to the brain.


News Image

Saul Priceman, Ph.D., City of Hope assistant professor in the Department of Hematology & Hematopoietic Cell Transplantation, and his research team have received an award from the California Institute for Regenerative Medicine to support a CAR T cell phase 1 clinical trial for the treatment of women with HER2-positive breast cancer that has spread to the brain.

Caitlin Buchanon Small | City of Hope

Diagnosed with a rare, fast-growing blood cancer and ineligible for a lifesaving stem cell transplant after failing chemotherapy, treatment with a breakthrough CAR T drug called Yescarta was Caitlin Buchanan's best hope for survival.


News Image

Study results will be presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.

News Image

City of Hope is now enrolling patients with multiple myeloma whose disease has relapsed, or is treatment-resistant, for a first-of-its kind chimeric antigen receptor (CAR) T cell therapy trial. It will also manufacture CAR T cells in its own laboratories.

test tubes

City of Hope’s clinical trials program is special because it was built with the same core values as the institution itself: an emphasis on leading-edge medicine, compassionate care, rapid bench-to-bedside research and always putting the patient first.